MICHAEL OKEKE: Open Payments
NPI 1114569811 · WINTER HAVEN, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$550 in 24 payments from 8 companies in 2025. Trend: 2023 $266 · 2024 $585 · 2025 $550
Food & beverage: $550
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 7 | $171 |
| ABBVIE INC. | 6 | $119 |
| E.R. Squibb & Sons, L.L.C. | 3 | $75 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $47 |
| Supernus Pharmaceuticals, Inc. | 2 | $37 |
| Dexcom, Inc. | 1 | $31 |
| Neurocrine BioSciences, Inc. | 1 | $24 |
Products named: VRAYLAR, LYBALVI, ARISTADA, COBENFY, CAPLYTA, REXULTI, Qelbree, DEXCOM G7 GSS (161).
Industry payments across FL — which companies pay providers there.
